Uveitis - Pipeline Review, H1 2017

Date: April 28, 2017
Pages: 186
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U8BD67BCFFDEN
Leaflet:

Download PDF Leaflet

Uveitis - Pipeline Review, H1 2017
Uveitis - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H1 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 5, 2, 29, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Uveitis - Overview
Uveitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uveitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uveitis - Companies Involved in Therapeutics Development
2-BBB Medicines BV
Aciont Inc
Aldeyra Therapeutics Inc
Apitope International NV
Astellas Pharma Inc
Bionomics Ltd
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd
Clearside BioMedical Inc
Coherus BioSciences Inc
Elasmogen Ltd
Endocyte Inc
Enzo Biochem Inc
EyeGate Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
HanAll Biopharma Co Ltd
Icon Bioscience Inc
Idera Pharmaceuticals Inc
InnoMedica Holding AG
KPI Therapeutics Inc
Midatech Pharma Plc
Mitotech SA
Nemus Bioscience Inc
Neuroptis Biotech
Novartis AG
Oculis ehf
OncoNOx ApS
Orchid Pharma Ltd
OSE Immunotherapeutics
Palatin Technologies Inc
Panacea Biotec Ltd
Panoptes Pharma GesmbH
Pfizer Inc
pSivida Corp
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
Santen Pharmaceutical Co Ltd
SynDevRx Inc
TxCell SA
Uveitis - Drug Profiles
2B-3201 - Drug Profile
abatacept - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
ADX-102 - Drug Profile
Antisense Oligonucleotide to Inhibit NLRP3 for Uveitis, Cystitis and Inflammatory Disorders - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile
ANV-103 - Drug Profile
ATXUV-1 - Drug Profile
B27-PD - Drug Profile
BNC-164 - Drug Profile
celecoxib - Drug Profile
Col-Treg - Drug Profile
CVX-001 - Drug Profile
cyclosporine SR - Drug Profile
dalazatide - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone sodium phosphate - Drug Profile
Drug for Chronic Uveitis - Drug Profile
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
EBI-031 - Drug Profile
EC-1669 - Drug Profile
ELN-21 - Drug Profile
ELN-22 - Drug Profile
EYS-606 - Drug Profile
fluocinolone acetonide SR - Drug Profile
FR-104 - Drug Profile
Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile
HL-036 - Drug Profile
HO-10 - Drug Profile
IVMED-10 - Drug Profile
IVMED-20 - Drug Profile
KPI-190 - Drug Profile
latanoprost SR - Drug Profile
LME-636 - Drug Profile
lodamin - Drug Profile
methotrexate - Drug Profile
NB-2222 - Drug Profile
NOP-3 - Drug Profile
OX-1001 - Drug Profile
piclidenoson - Drug Profile
PL-8177 - Drug Profile
plastoquinone decyl triphenylphosphonium bromide - Drug Profile
PP-001 - Drug Profile
PPL-003 - Drug Profile
RP-0217 - Drug Profile
sarilumab - Drug Profile
sirolimus - Drug Profile
Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis - Drug Profile
Small Molecules for Posterior Uveitis - Drug Profile
Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile
Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
tesidolumab - Drug Profile
triamcinolone acetonide - Drug Profile
Uveitis - Dormant Projects
Uveitis - Discontinued Products
Uveitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Uveitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Products under Development by Companies, H1 2017 (Contd.3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Uveitis - Pipeline by 2-BBB Medicines BV, H1 2017
Uveitis - Pipeline by Aciont Inc, H1 2017
Uveitis - Pipeline by Aldeyra Therapeutics Inc, H1 2017
Uveitis - Pipeline by Apitope International NV, H1 2017
Uveitis - Pipeline by Astellas Pharma Inc, H1 2017
Uveitis - Pipeline by Bionomics Ltd, H1 2017
Uveitis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Uveitis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Uveitis - Pipeline by Clearside BioMedical Inc, H1 2017
Uveitis - Pipeline by Coherus BioSciences Inc, H1 2017
Uveitis - Pipeline by Elasmogen Ltd, H1 2017
Uveitis - Pipeline by Endocyte Inc, H1 2017
Uveitis - Pipeline by Enzo Biochem Inc, H1 2017
Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
Uveitis - Pipeline by Eyevensys SAS, H1 2017
Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Uveitis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Uveitis - Pipeline by Icon Bioscience Inc, H1 2017
Uveitis - Pipeline by Idera Pharmaceuticals Inc, H1 2017
Uveitis - Pipeline by InnoMedica Holding AG, H1 2017
Uveitis - Pipeline by KPI Therapeutics Inc, H1 2017
Uveitis - Pipeline by Midatech Pharma Plc, H1 2017
Uveitis - Pipeline by Mitotech SA, H1 2017
Uveitis - Pipeline by Nemus Bioscience Inc, H1 2017
Uveitis - Pipeline by Neuroptis Biotech, H1 2017
Uveitis - Pipeline by Novartis AG, H1 2017
Uveitis - Pipeline by Oculis ehf, H1 2017
Uveitis - Pipeline by OncoNOx ApS, H1 2017
Uveitis - Pipeline by Orchid Pharma Ltd, H1 2017
Uveitis - Pipeline by OSE Immunotherapeutics, H1 2017
Uveitis - Pipeline by Palatin Technologies Inc, H1 2017
Uveitis - Pipeline by Panacea Biotec Ltd, H1 2017
Uveitis - Pipeline by Panoptes Pharma GesmbH, H1 2017
Uveitis - Pipeline by Pfizer Inc, H1 2017
Uveitis - Pipeline by pSivida Corp, H1 2017
Uveitis - Pipeline by Re-Pharm Ltd, H1 2017
Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Uveitis - Pipeline by Sandoz International GmbH, H1 2017
Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
Uveitis - Pipeline by SynDevRx Inc, H1 2017
Uveitis - Pipeline by TxCell SA, H1 2017
Uveitis - Dormant Projects, H1 2017
Uveitis - Dormant Projects, H1 2017 (Contd.1), H1 2017
Uveitis - Dormant Projects, H1 2017 (Contd.2), H1 2017
Uveitis - Discontinued Products, H1 2017

LIST OF FIGURES

Number of Products under Development for Uveitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

COMPANIES MENTIONED

2-BBB Medicines BV
Aciont Inc
Aldeyra Therapeutics Inc
Apitope International NV
Astellas Pharma Inc
Bionomics Ltd
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd
Clearside BioMedical Inc
Coherus BioSciences Inc
Elasmogen Ltd
Endocyte Inc
Enzo Biochem Inc
EyeGate Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
HanAll Biopharma Co Ltd
Icon Bioscience Inc
Idera Pharmaceuticals Inc
InnoMedica Holding AG
KPI Therapeutics Inc
Midatech Pharma Plc
Mitotech SA
Nemus Bioscience Inc
Neuroptis Biotech
Novartis AG
Oculis ehf
OncoNOx ApS
Orchid Pharma Ltd
OSE Immunotherapeutics
Palatin Technologies Inc
Panacea Biotec Ltd
Panoptes Pharma GesmbH
Pfizer Inc
pSivida Corp
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
Santen Pharmaceutical Co Ltd
SynDevRx Inc
TxCell SA
Skip to top


Anterior Uveitis - Pipeline Review, H1 2016 US$ 2,000.00 Mar, 2016 · 59 pages
Uveitis - Pipeline Review, H2 2017 US$ 2,000.00 Sep, 2017 · 208 pages
Anterior Uveitis - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 55 pages
Posterior Uveitis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 65 pages
Posterior Uveitis - Pipeline Review, H1 2016 US$ 2,000.00 Apr, 2016 · 64 pages

Ask Your Question

Uveitis - Pipeline Review, H1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: